Unlock instant, AI-driven research and patent intelligence for your innovation.

Disulfide bond stabilized polypeptide compositions and methods of use

A stable and genomic technology, applied in biochemical equipment and methods, drug combination, expression enhancement stability/folded protein fusion, etc., can solve problems such as poor stability and limited half-life of therapeutic enzymes

Pending Publication Date: 2021-11-09
AMICUS THERAPEUTICS INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, recombinant wild-type peptides are generally less stable at neutral pH and are rapidly degraded in serum
This greatly limits the half-life of the therapeutic enzyme as it is delivered by intravenous infusion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Disulfide bond stabilized polypeptide compositions and methods of use
  • Disulfide bond stabilized polypeptide compositions and methods of use
  • Disulfide bond stabilized polypeptide compositions and methods of use

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0164] Example 1: Identification of amino acid residues for cysteine ​​substitution of wild-type α-GAL

[0165] Examination of potential sites for substitution of cysteine ​​residues in the crystal structure of dimerized α-GAL (PDB ID 3HG3), resulting in additional disulfide bonds for enhanced stability ( Figure 1A ). NAMD with CHARMM force field was used for analysis. Based on the analysis, the cysteine ​​mutants shown in Table 8 were prepared using standard methods of site-directed mutagenesis.

[0166]

[0167] see also Figure 1B . Amino acid sequences are provided in Table 1.

example 2

[0168] Example 2: Dimerization and enzymatic activity of modified α-GAL

[0169] The formation of disulfide-bonded dimers of modified α-GAL was examined in cell lysates and media ( Figure 2A ). Clones of each α-GAL construct were transiently expressed in 293HEK cells. Cell lysates and media were run on a 4%-12% gradient SDS-PAGE and transferred to nitrocellulose. α-GAL was detected by western blotting with rabbit monoclonal anti-α-GAL 1:2000 (abcam ab168341).

[0170] Electrophoresis and Western blotting were performed on reduced and non-reduced samples. As shown in Figure 2, the M51C-G360C and D233C-I359C versions of α-GAL readily formed disulfide-bonded α-GAL dimers.

[0171] To prepare samples, 1 x 10^6 cells with transient expression of the α-GAL construct were harvested. Cells were lysed in 500 ul of 20 mM sodium phosphate buffer pH 6.5, 0.25% TX-100. Cell lysates were centrifuged at 10,000 g for 2 min, and the supernatant was transferred to a new tube. Transfer...

example 3

[0173] Example 3: Stability analysis of modified α-GAL over time in an acidic environment

[0174] To test pH stability over 24 h, transiently expressed mutant and wild-type α-GAL were captured using concanavalin A (ConA) agarose pull-down according to standard methods. Dilute the ConA eluate in pH 4.6 buffer or pH 7.4 buffer. Samples were pre-incubated at pH 4.6 or 7.4 for 0, 0.5, 1, 2, 4, 5 and 24 hours.

[0175] To measure enzyme activity, pH 4.6 buffer was added to each sample and activity was tested on 4-MUG substrate. The reaction mixture was incubated at 37°C for 1 hour. The reaction was stopped by adding 125 uL of stop buffer (0.4M Glycine-NaOH, pH 10.8) Fluorescence was read with a Spectramax plate reader: Excitation: 360nm, Emission: 450nm. The results are shown in Figure 3A middle.

[0176] For long-term stability testing, transiently expressed modified and wild-type α-GAL were isolated from culture medium, enriched and purified using ConA Sepharose beads as...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are polypeptides comprising one or more non-native cysteine residues that form a disulfide bridge between non-native cysteines within the protein or between non-native cysteines of two monomers of the protein. Such modified human polypeptides are useful in treatment of genetic diseases via enzyme replacement therapy and / or gene therapy.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application No. 62 / 744,069, filed October 10, 2018, which is hereby incorporated by reference in its entirety. Background technique [0003] Genetic diseases can be treated by enzyme replacement therapy using recombinant polypeptides or gene therapy using nucleic acids encoding recombinant proteins. For example, Fabry disease can be treated using recombinant alpha-galactosidase A or small molecule chaperones such as 1-deoxygalactonojirimycin (Migalastat). However, recombinant wild-type polypeptides are generally less stable at neutral pH and are rapidly degraded in serum. This greatly limits the half-life of the therapeutic enzyme as it is delivered by intravenous infusion. Contents of the invention [0004] In certain aspects, gene therapy vectors comprising a nucleic acid construct comprising: a nucleic acid encoding a stabilized form of a protein useful for tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/47A61K48/00
CPCC12Y302/01022C12N9/2465C12Y301/02022A61K38/00C12N2750/14143A61K48/005C12N15/86C12N9/2402A61K38/465A61K38/47A61P3/00A61P43/00C12Y302/01017C07K2319/35A61K48/0033A61K48/0058C12N15/79C12N2800/00C07H21/04
Inventor H·杜刘策峰
Owner AMICUS THERAPEUTICS INC